27.12.2020

11:42

FDA approves adjuvant osimertinib for early stage egfr nsclc

The FDA has approved osimertinib for use as an adjuvant treatment following tumor resection in patients with non–small cell lung cancer whose tumors harbor EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test

OncLive

מן הרשת

15.12.2020

13:09

המוח שלך בריא?

מיגרנה, שבץ, אלצהיימר, פרקינסון, אפילפסיה ועוד... 6 מתוך 10 אנשים יחלו במחלה נוירולוגית כלשהי. במספר צעדים פשוטים אפשר לשמור גם על מוח בריא

פרופ' דוד טנה, Ynet

מן הרשת

13.12.2020

12:18

FDA Approves Durvalumab for Fixed-Dose Use in NSCLC

The FDA has approved durvalumab for an additional dosing option, a fixed dose of 1500 mg every 4 weeks, in the approved indications of unresectable stage III non-small cell lung cancer after chemoradiation and previously treated advanced bladder cancer

OncLive

מן הרשת

13.12.2020

11:50

Higher Risk of Falls/Fractures With Androgen Receptor Inhibitors

An increase in the risk of falling and fracturing bones was associated with the use of androgen receptor inhibitors (ARIs) for the treatment of prostate cancer, a systematic review and meta-analysis suggests

Medscape

מן הרשת

13.12.2020

11:49

High-Risk Prostate Cancer Patients Can Wait 6 Months for Surgery: Study

Can be considered low priority procedure during COVID-19 pandemic, researchers say

Medpage Today

מן הרשת

13.12.2020

11:47

Molecular subtypes of fully resected clear cell renal cell carcinoma

Molecular subtypes of fully resected clear cell renal cell carcinoma are prognostic for risk of relapse and may impact adjuvant treatment

uroonco

מן הרשת

13.12.2020

11:46

Probiotic Supplementation Modulates Gut Microbiome and Clinical Outcome

Cancer Medicine

מן הרשת

13.12.2020

11:44

Management and survival of patients with retroperitoneal recurrences following radical nephrectomy

Results from a multi-institutional international datasets

uroonco

מן הרשת

13.12.2020

11:43

Clinical and Pathological Characteristics of Metastatic Renal Cell Carcinoma

Clinical and Pathological Characteristics of Metastatic Renal Cell Carcinoma Patients Needing a Second-Line Therapy: A Systematic Review

Uro Today

מן הרשת

13.12.2020

11:41

Stereotactic Radiotherapy for the Metastatic Renal Cell Carcinoma

Stereotactic Radiotherapy for the Treatment of Patients With Oligo-progressive Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor: Data From the Real World

Uro Today

מן הרשת

13.12.2020

11:40

Inguinal Lymph Node Metastasis of Bladder Carcinoma After Radical Cystectomy

A Case Report and Review of Literature - Beyond the Abstract

Uro Today

מן הרשת

13.12.2020

11:38

Trends in Initial Systemic Therapy for Elderly Patients With Metastatic Clear Cell RCC

Renal Cell Carcinoma

מן הרשת

13.12.2020

11:33

FGFR3 Status in Urothelial Carcinoma

FGFR3 Status Associated With Differential Sensitivity to Platinum-Based Chemotherapy in Urothelial Carcinoma

Urology

מן הרשת

13.12.2020

11:31

Post-surgical ctDNA-positivity in patients with MIUC

Post-surgical ctDNA-positivity in patients with MIUC associates with higher risk of disease recurrence and identifies patients that may benefit from adjuvant atezolizumab therapy

ESMO

מן הרשת

08.12.2020

11:55

Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer

updated results from a randomised, controlled, open-label, phase 3 trial

The Lancet Oncology

מן הרשת

FDA approves adjuvant osimertinib for early stage egfr nsclc

The FDA has approved osimertinib for use as an adjuvant treatment following tumor resection in patients with non–small cell lung cancer whose tumors harbor EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test

המוח שלך בריא?

מיגרנה, שבץ, אלצהיימר, פרקינסון, אפילפסיה ועוד... 6 מתוך 10 אנשים יחלו במחלה נוירולוגית כלשהי. במספר צעדים פשוטים אפשר לשמור גם על מוח בריא

FDA Approves Durvalumab for Fixed-Dose Use in NSCLC

The FDA has approved durvalumab for an additional dosing option, a fixed dose of 1500 mg every 4 weeks, in the approved indications of unresectable stage III non-small cell lung cancer after chemoradiation and previously treated advanced bladder cancer

Higher Risk of Falls/Fractures With Androgen Receptor Inhibitors

An increase in the risk of falling and fracturing bones was associated with the use of androgen receptor inhibitors (ARIs) for the treatment of prostate cancer, a systematic review and meta-analysis suggests

High-Risk Prostate Cancer Patients Can Wait 6 Months for Surgery: Study

Can be considered low priority procedure during COVID-19 pandemic, researchers say

Molecular subtypes of fully resected clear cell renal cell carcinoma

Molecular subtypes of fully resected clear cell renal cell carcinoma are prognostic for risk of relapse and may impact adjuvant treatment

Probiotic Supplementation Modulates Gut Microbiome and Clinical Outcome

Management and survival of patients with retroperitoneal recurrences following radical nephrectomy

Results from a multi-institutional international datasets

Clinical and Pathological Characteristics of Metastatic Renal Cell Carcinoma

Clinical and Pathological Characteristics of Metastatic Renal Cell Carcinoma Patients Needing a Second-Line Therapy: A Systematic Review

Stereotactic Radiotherapy for the Metastatic Renal Cell Carcinoma

Stereotactic Radiotherapy for the Treatment of Patients With Oligo-progressive Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor: Data From the Real World

Inguinal Lymph Node Metastasis of Bladder Carcinoma After Radical Cystectomy

A Case Report and Review of Literature - Beyond the Abstract

Trends in Initial Systemic Therapy for Elderly Patients With Metastatic Clear Cell RCC

FGFR3 Status in Urothelial Carcinoma

FGFR3 Status Associated With Differential Sensitivity to Platinum-Based Chemotherapy in Urothelial Carcinoma

Post-surgical ctDNA-positivity in patients with MIUC

Post-surgical ctDNA-positivity in patients with MIUC associates with higher risk of disease recurrence and identifies patients that may benefit from adjuvant atezolizumab therapy

Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer

updated results from a randomised, controlled, open-label, phase 3 trial

03.06.2021

מחקרים וחדשות רפואה

תגובות אחרונות

7 הכי נקראות